Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Altimmune announces new preclinical data for AdCOVID » 07:03
05/10/21
05/10
07:03
05/10/21
07:03
ALT

Altimmune

$13.28 /

+0.305 (+2.35%)

Altimmune announced…

Altimmune announced results from a preclinical study of AdCOVID in a SARS-CoV-2 challenge model of infection. In this study, a single intranasal dose of AdCOVID provided sterilizing immunity in the lungs of vaccinated mice, in contrast to the development of dense pulmonary infection and disease in the lungs of non-vaccinated mice following infection with SARS-CoV-2. AdCOVID is a novel, single-dose intranasal vaccine candidate for COVID-19. In the current study, performed in collaboration with UAB, K18-hACE2 transgenic mice, which are highly permissive for SARS-CoV-2 replication and considered one of the best models for COVID-19, were vaccinated with a single intranasal dose of AdCOVID and challenged one month later with live SARS-CoV-2 virus. When the lungs of the mice were evaluated for infectious SARS-CoV-2 virus, no detectable levels of infectious virus were observed in the lungs of vaccinated mice, representing a greater than one million-fold reduction of infectious virus compared to the non-vaccinated controls. This demonstration of sterilizing immunity is consistent with the stimulation of local and systemic immunity by AdCOVID shown in previous animal studies, including high serum neutralizing antibody and T cell responses, and most importantly, mucosal IgA responses in the respiratory tract. The ongoing AdCOVID Phase 1 clinical trial is evaluating the safety and immunogenicity of AdCOVID following a single dose or two intranasal doses administered one month apart and is expected to report topline data in June 2021. The trial is evaluating three different dose levels of AdCOVID and will measure local mucosal IgA responses in the nasaopharyngeal cavity, systemic serum immune responses, including serum neutralizing antibody relative to COVID-19 convalescent serum, and T cell responses directed against the spike protein receptor binding domain.

ShowHide Related Items >><<
ALT Altimmune
$13.28 /

+0.305 (+2.35%)

ALT Altimmune
$13.28 /

+0.305 (+2.35%)

03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
02/18/21 B. Riley
Altimmune price target raised to $41 from $28 at B. Riley Securities
02/17/21 Piper Sandler
Piper remains bullish on Altimmune after FDA clears Covid vaccine trial
02/10/21 Guggenheim
Altimmune initiated with a Buy at Guggenheim
ALT Altimmune
$13.28 /

+0.305 (+2.35%)

  • 14
    Jul
ALT Altimmune
$13.28 /

+0.305 (+2.35%)

ALT Altimmune
$13.28 /

+0.305 (+2.35%)

Over a week ago
Periodicals
Upcoming COVID-19 vaccines could be in pill or spray forms, WSJ report » 06:33
05/03/21
05/03
06:33
05/03/21
06:33
SNY

Sanofi

$50.44 /

-0.36 (-0.71%)

, ALT

Altimmune

$14.48 /

+0.29 (+2.04%)

, PFE

Pfizer

$38.66 /

+0.05 (+0.13%)

, BNTX

BioNTech

$188.40 /

+8.89 (+4.95%)

, MRNA

Moderna

$178.69 /

+3.26 (+1.86%)

Upcoming COVID-19…

Upcoming COVID-19 vaccines could potentially be available as a pill or nasal spray, which would be easier to store and transport than current vaccines, Peter Loftus and Gregory Zuckerman of The Wall Street Journal report. Currently, companies such as Sanofi (SNY), Altimmune (ALT), and Gristone Oncology have been developing these new vaccines that have the potential to elicit longer-lasting immune responses and may be more potent against variant strains. Vaccines currently authorized in the U.S. are from Pfizer (PFE) and BioNTech (BNTX), and (MRNA). Reference Link

ShowHide Related Items >><<
SNY Sanofi
$50.44 /

-0.36 (-0.71%)

PFE Pfizer
$38.66 /

+0.05 (+0.13%)

MRNA Moderna
$178.69 /

+3.26 (+1.86%)

BNTX BioNTech
$188.40 /

+8.89 (+4.95%)

ALT Altimmune
$14.48 /

+0.29 (+2.04%)

SNY Sanofi
$50.44 /

-0.36 (-0.71%)

04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
ALT Altimmune
$14.48 /

+0.29 (+2.04%)

03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
02/18/21 B. Riley
Altimmune price target raised to $41 from $28 at B. Riley Securities
02/17/21 Piper Sandler
Piper remains bullish on Altimmune after FDA clears Covid vaccine trial
02/10/21 Guggenheim
Altimmune initiated with a Buy at Guggenheim
PFE Pfizer
$38.66 /

+0.05 (+0.13%)

04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
04/09/21
Pfizer to host conference call
BNTX BioNTech
$188.40 /

+8.89 (+4.95%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
MRNA Moderna
$178.69 /

+3.26 (+1.86%)

04/29/21 Piper Sandler
Piper keeps $234 target on Moderna after raised Covid vaccine guidance
04/15/21 Piper Sandler
Moderna price target raised to $234 from $208 at Piper Sandler
04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
SNY Sanofi
$50.44 /

-0.36 (-0.71%)

PFE Pfizer
$38.66 /

+0.05 (+0.13%)

MRNA Moderna
$178.69 /

+3.26 (+1.86%)

ALT Altimmune
$14.48 /

+0.29 (+2.04%)

  • 23
    Jul
  • 14
    Jul
  • 19
    May
SNY Sanofi
$50.44 /

-0.36 (-0.71%)

PFE Pfizer
$38.66 /

+0.05 (+0.13%)

MRNA Moderna
$178.69 /

+3.26 (+1.86%)

BNTX BioNTech
$188.40 /

+8.89 (+4.95%)

SNY Sanofi
$50.44 /

-0.36 (-0.71%)

PFE Pfizer
$38.66 /

+0.05 (+0.13%)

MRNA Moderna
$178.69 /

+3.26 (+1.86%)

BNTX BioNTech
$188.40 /

+8.89 (+4.95%)

ALT Altimmune
$14.48 /

+0.29 (+2.04%)

PFE Pfizer
$38.66 /

+0.05 (+0.13%)

MRNA Moderna
$178.69 /

+3.26 (+1.86%)

BNTX BioNTech
$188.40 /

+8.89 (+4.95%)

Conference/Events
Altimmune management to meet virtually with JMP Securities » 04:55
04/21/21
04/21
04:55
04/21/21
04:55
ALT

Altimmune

$11.82 /

+0.025 (+0.21%)

Virtual Meeting to be…

Virtual Meeting to be held on April 21 hosted by JMP Securities.

ShowHide Related Items >><<
ALT Altimmune
$11.82 /

+0.025 (+0.21%)

ALT Altimmune
$11.82 /

+0.025 (+0.21%)

03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
02/18/21 B. Riley
Altimmune price target raised to $41 from $28 at B. Riley Securities
02/17/21 Piper Sandler
Piper remains bullish on Altimmune after FDA clears Covid vaccine trial
02/10/21 Guggenheim
Altimmune initiated with a Buy at Guggenheim
ALT Altimmune
$11.82 /

+0.025 (+0.21%)

  • 14
    Jul
ALT Altimmune
$11.82 /

+0.025 (+0.21%)

ALT Altimmune
$11.82 /

+0.025 (+0.21%)

Conference/Events
Altimmune management to meet virtually with JMP Securities » 15:06
04/15/21
04/15
15:06
04/15/21
15:06
ALT

Altimmune

$12.69 /

-0.25 (-1.93%)

Virtual Meeting to be…

Virtual Meeting to be held on April 21 hosted by JMP Securities.

ShowHide Related Items >><<
ALT Altimmune
$12.69 /

-0.25 (-1.93%)

ALT Altimmune
$12.69 /

-0.25 (-1.93%)

03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
02/18/21 B. Riley
Altimmune price target raised to $41 from $28 at B. Riley Securities
02/17/21 Piper Sandler
Piper remains bullish on Altimmune after FDA clears Covid vaccine trial
02/10/21 Guggenheim
Altimmune initiated with a Buy at Guggenheim
ALT Altimmune
$12.69 /

-0.25 (-1.93%)

  • 14
    Jul
ALT Altimmune
$12.69 /

-0.25 (-1.93%)

ALT Altimmune
$12.69 /

-0.25 (-1.93%)

Over a month ago
Hot Stocks
Altimmune reports data from phase 1B clinical trial of NasoShield » 07:05
04/01/21
04/01
07:05
04/01/21
07:05
ALT

Altimmune

$14.13 /

+0.57 (+4.20%)

Altimmune reported…

Altimmune reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in healthy volunteers. The clinical trial was conducted with support from the Biomedical Advanced Research and Development Authority. The trial enrolled 42 healthy subjects who received intranasally administered NasoShield or saline placebo and were then monitored for 6 months post-dosing. The primary endpoint was the safety and tolerability of NasoShield. The primary immunogenicity readouts included the serum binding antibody to protective antigen and anthrax toxin blocking antibody responses at 28- and 56-days post-dose administration. Stimulation of the mucosal IgA immune response in the nasal cavity was also assessed. "The clinical data from the Phase 1b trial showed that: serum binding antibody responses to the protective antigen of Bacillus anthracis, the bacterium and causative agent of anthrax, were significantly greater than in the placebo arm; antibody responses blocking anthrax toxin were blunted compared to protective antigen antibody responses and were low compared to prior studies conducted with BioThrax, the only approved anthrax vaccine; Notably, as with Altimmune's other intranasally administered replication-deficient adenovirus vaccines, nasal mucosal IgA responses specific for protective antigen were observed in up to 80% of subjects post-vaccination; and the safety and tolerability of NasoShield was excellent and comparable to intranasal saline placebo in both the number and characteristics of adverse or reactogenicity events, consistent with other clinical trials of Altimmune's intranasal vaccine candidates," the company said.

ShowHide Related Items >><<
ALT Altimmune
$14.13 /

+0.57 (+4.20%)

ALT Altimmune
$14.13 /

+0.57 (+4.20%)

03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
02/18/21 B. Riley
Altimmune price target raised to $41 from $28 at B. Riley Securities
02/17/21 Piper Sandler
Piper remains bullish on Altimmune after FDA clears Covid vaccine trial
02/10/21 Guggenheim
Altimmune initiated with a Buy at Guggenheim
ALT Altimmune
$14.13 /

+0.57 (+4.20%)

  • 14
    Jul
ALT Altimmune
$14.13 /

+0.57 (+4.20%)

ALT Altimmune
$14.13 /

+0.57 (+4.20%)

Recommendations
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler » 13:07
03/26/21
03/26
13:07
03/26/21
13:07
ALT

Altimmune

$13.52 /

-0.615 (-4.35%)

, AZN

AstraZeneca

$50.02 /

+0.34 (+0.68%)

AstraZeneca's (AZN)…

AstraZeneca's (AZN) announced plans yesterday for a Phase 1 study of an intranasal ChAdOx1 nCoV-19 vaccine signals large pharma's interest in intranasal vaccines, Piper Sandler analyst Yasmeen Rahimi tells investors in a research note. The analyst believes the news "opens the door to strategic interest" in Altimmune's (ALT) single-dose intranasal vaccine AdCOVID especially with Phase 1 safety and immunogenicity data in 180 healthy volunteers expected in Q2. Rahimi keeps an Overweight rating on Altimmune with an $80 price target.

ShowHide Related Items >><<
AZN AstraZeneca
$50.02 /

+0.34 (+0.68%)

ALT Altimmune
$13.52 /

-0.615 (-4.35%)

ALT Altimmune
$13.52 /

-0.615 (-4.35%)

02/18/21 B. Riley
Altimmune price target raised to $41 from $28 at B. Riley Securities
02/17/21 Piper Sandler
Piper remains bullish on Altimmune after FDA clears Covid vaccine trial
02/10/21 Guggenheim
Altimmune initiated with a Buy at Guggenheim
12/30/20 Piper Sandler
2021 is the 'breakout year' for Altimmune, says Piper Sandler
AZN AstraZeneca
$50.02 /

+0.34 (+0.68%)

03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 Jefferies
AstraZeneca upgraded to Buy from Hold at Jefferies
AZN AstraZeneca
$50.02 /

+0.34 (+0.68%)

ALT Altimmune
$13.52 /

-0.615 (-4.35%)

  • 14
    Jul
AZN AstraZeneca
$50.02 /

+0.34 (+0.68%)

AZN AstraZeneca
$50.02 /

+0.34 (+0.68%)

ALT Altimmune
$13.52 /

-0.615 (-4.35%)

AZN AstraZeneca
$50.02 /

+0.34 (+0.68%)

ALT Altimmune
$13.52 /

-0.615 (-4.35%)

Hot Stocks
Altimmune, Summit Biosciences partner for nasal spray presentation of AdCOVID » 07:09
03/22/21
03/22
07:09
03/22/21
07:09
ALT

Altimmune

$16.47 /

-0.9 (-5.18%)

Altimmune announced that…

Altimmune announced that it has retained Summit Biosciences to manufacture a metered nasal spray presentation of AdCOVID, its intranasal COVID-19 vaccine candidate. AdCOVID is an adenovirus-vector vaccine designed to stimulate a broad immune response following a single vaccination that includes both systemic immunity and local immunity in the nasal cavity and respiratory tract. AdCOVID is currently being evaluated in a Phase 1 clinical trial. The Phase 1 trial is evaluating the safety and immunogenicity of AdCOVID in healthy adult volunteers between the ages of 18 and 55. Subjects will receive AdCOVID at one of three dose levels administered as a nasal spray. In addition to the primary study endpoint of safety and tolerability, the immunogenicity of AdCOVID will be evaluated by serum IgG binding and neutralizing antibody titers, mucosal IgA antibody from nasal samples, and T cell responses. Altimmune anticipates having a data readout from this Phase 1 trial in Q2 2021.

ShowHide Related Items >><<
ALT Altimmune
$16.47 /

-0.9 (-5.18%)

ALT Altimmune
$16.47 /

-0.9 (-5.18%)

02/18/21 B. Riley
Altimmune price target raised to $41 from $28 at B. Riley Securities
02/17/21 Piper Sandler
Piper remains bullish on Altimmune after FDA clears Covid vaccine trial
02/10/21 Guggenheim
Altimmune initiated with a Buy at Guggenheim
12/30/20 Piper Sandler
2021 is the 'breakout year' for Altimmune, says Piper Sandler
ALT Altimmune
$16.47 /

-0.9 (-5.18%)

  • 14
    Jul
ALT Altimmune
$16.47 /

-0.9 (-5.18%)

ALT Altimmune
$16.47 /

-0.9 (-5.18%)

Conference/Events
Altimmune management to meet virtually with Piper Sandler » 04:55
03/05/21
03/05
04:55
03/05/21
04:55
ALT

Altimmune

$13.20 /

-1.11 (-7.76%)

Virtual Meeting to be…

Virtual Meeting to be held on March 5 hosted by Piper Sandler.

ShowHide Related Items >><<
ALT Altimmune
$13.20 /

-1.11 (-7.76%)

ALT Altimmune
$13.20 /

-1.11 (-7.76%)

02/18/21 B. Riley
Altimmune price target raised to $41 from $28 at B. Riley Securities
02/17/21 Piper Sandler
Piper remains bullish on Altimmune after FDA clears Covid vaccine trial
02/10/21 Guggenheim
Altimmune initiated with a Buy at Guggenheim
12/30/20 Piper Sandler
2021 is the 'breakout year' for Altimmune, says Piper Sandler
ALT Altimmune
$13.20 /

-1.11 (-7.76%)

  • 14
    Jul
ALT Altimmune
$13.20 /

-1.11 (-7.76%)

ALT Altimmune
$13.20 /

-1.11 (-7.76%)

Conference/Events
Altimmune management to meet virtually with Piper Sandler » 12:24
03/04/21
03/04
12:24
03/04/21
12:24
ALT

Altimmune

$13.47 /

-0.84 (-5.87%)

Virtual Meeting to be…

Virtual Meeting to be held on March 5 hosted by Piper Sandler.

ShowHide Related Items >><<
ALT Altimmune
$13.47 /

-0.84 (-5.87%)

ALT Altimmune
$13.47 /

-0.84 (-5.87%)

02/18/21 B. Riley
Altimmune price target raised to $41 from $28 at B. Riley Securities
02/17/21 Piper Sandler
Piper remains bullish on Altimmune after FDA clears Covid vaccine trial
02/10/21 Guggenheim
Altimmune initiated with a Buy at Guggenheim
12/30/20 Piper Sandler
2021 is the 'breakout year' for Altimmune, says Piper Sandler
ALT Altimmune
$13.47 /

-0.84 (-5.87%)

  • 14
    Jul
ALT Altimmune
$13.47 /

-0.84 (-5.87%)

ALT Altimmune
$13.47 /

-0.84 (-5.87%)

Hot Stocks
Altimmune commences enrollment in AdCOVID Phase 1 clinical trial » 07:26
02/25/21
02/25
07:26
02/25/21
07:26
ALT

Altimmune

$19.54 /

+0.34 (+1.77%)

Altimmune has commenced…

Altimmune has commenced enrollment in its Phase 1 clinical trial of AdCOVID, which is designed to evaluate a needle-free intranasal delivery approach for vaccination against COVID-19. Altimmune believes AdCOVID has the potential to become a leading candidate for COVID-19 vaccination based on its ease of administration, and the potential for reduced disease transmission, and cold chain-free vaccine distribution, if the product is demonstrated to have extended stability at room temperature. As demonstrated in the NasoShield and NasoVax clinical trials, the Company believes the expected attributes of AdCOVID make it ideally suited for use in a pediatric setting as the intranasal administration and expected tolerability profile are well suited to meet the needs of children. The Phase 1 clinical trial will evaluate the safety and immunogenicity of AdCOVID in up to 180 healthy adult volunteers between the ages of 18 and 55. Subjects will receive AdCOVID at one of three dose levels administered as a nasal spray. In addition to the primary study endpoint of safety and tolerability, the immunogenicity of AdCOVID will be evaluated by serum IgG binding and neutralizing antibody titers, mucosal IgA antibody from nasal samples, and T cell responses. Altimmune anticipates having a full data readout from this Phase 1 study in Q2 2021.

ShowHide Related Items >><<
ALT Altimmune
$19.54 /

+0.34 (+1.77%)

ALT Altimmune
$19.54 /

+0.34 (+1.77%)

02/18/21 B. Riley
Altimmune price target raised to $41 from $28 at B. Riley Securities
02/17/21 Piper Sandler
Piper remains bullish on Altimmune after FDA clears Covid vaccine trial
02/10/21 Guggenheim
Altimmune initiated with a Buy at Guggenheim
12/30/20 Piper Sandler
2021 is the 'breakout year' for Altimmune, says Piper Sandler
ALT Altimmune
$19.54 /

+0.34 (+1.77%)

  • 14
    Jul
ALT Altimmune
$19.54 /

+0.34 (+1.77%)

ALT Altimmune
$19.54 /

+0.34 (+1.77%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.